Sushant Kumar

Sushant Kumar, PhD, is an accomplished professional in the biotechnology and pharmaceutical industries with extensive experience in research and development, business development, and investment management. Currently serving as an R&D and Business Development Advisor at BioSapient LLC and Managing Director at Edison Group since April 2017, Sushant has also founded and led Tarus Therapeutics as President & CEO, where innovative adenosine receptor antagonists were developed. Previous positions include Co-Founder and CEO of GCATx, focusing on genomically-defined cancers, and Co-Founder and Managing Partner at Ardana Capital Management, specializing in investments in novel healthcare companies. Sushant's early career included a partnership at Mehta Partners, contributing to significant transactions within the BioPharma sector. Educationally, Sushant earned a PhD in Molecular Biology from Rutgers Robert Wood Johnson Medical School and completed a post-doctoral fellowship at Harvard Medical School, focusing on targeted protein degradation mechanisms.